01.12.2014 | Methodology | Ausgabe 1/2014 Open Access
Revised French guidelines for the diagnosis and management of migraine in adults and children
- Zeitschrift:
- The Journal of Headache and Pain > Ausgabe 1/2014
Wichtige Hinweise
Electronic supplementary material
The online version of this article (doi:10.1186/1129-2377-15-2) contains supplementary material, which is available to authorized users.
Competing interests
MLM declares conflicts of interest with: Allergan, Almirall SAS, AstraZeneca Pharmaceuticals, GlaxoSmithKline Inc, Grunenthal, Eli Lilly & Company, Johnson & Johnson, Medtronic, Menarini, Merck, Pierre Fabre, Pfizer Inc, Sanofi-Aventis, UCB, Zambon.
DV declares conflicts of interest with: Allergan, Almirall, BMS, MSD, GSK, Janssen Cilag, Menarini, MSD, Pfizer, Sanofi-Aventis, UCB, Astra-Zeneca, Zambon.
GG declares conflicts of interest with: Allergan, AstraZeneca Pharmaceuticals, Menarini, Merck, Pfizer Inc., Zambon.
CL declares conflicts of interest with: Allergan, Almirall, AstraZeneca Pharmaceuticals, Boehringer, GlaxoSmithKline Inc, Grunenthal, Lilly, Menarini, Merck, SanofiAventis, Pfizer Inc., UCB-Schwarz-Pharma, Zambon.
AD declares conflicts of interest with: Allergan, Almirall SAS, AstraZeneca Pharmaceuticals, GlaxoSmithKline Inc, Grunenthal, Merck, Menarini, Orkyn, Pfizer Inc, Zambon.
Authors’ contributions
MLM, DV, GG, CL and AD drafted the manuscript. All authors read and approved the final manuscript.
